MISSISSAUGA, Ontario, Oct. 27, 2009 - Cipher Pharmaceuticals Inc. (TSX: DND), announced today that Larry Andrews, President and Chief Executive Officer of the Company, is presenting at the 8th Annual BIO Investor Forum, which is being held at the Palace Hotel in San Francisco, California from October 28-29, 2009. Mr. Andrews will provide an update on the Company’s drug development activities and plans. Cipher’s presentation will take place on Wednesday, October 28, 2009 at 2:30 pm Pacific Time.
About Cipher Pharmaceuticals Inc. Cipher Pharmaceuticals is a drug development company focused on commercializing novel formulations of successful, currently marketed molecules using advanced drug delivery technologies. Cipher’s strategy is to in-license products that incorporate proven drug delivery technologies and advance them through the clinical development and regulatory approval stages, after which the products are out-licensed to international partners. Because Cipher’s products are based on proven technology platforms applied to currently marketed drugs, they are expected to have lower approval risk, shorter development timelines and significantly lower development costs. The Company’s lead compound, CIP-FENOFIBRATE, received final approval from the U.S. Food and Drug Administration and Health Canada in the first quarter of 2006. The product is being marketed in the United States by Kowa Pharmaceuticals America under the label Lipofen®. In addition, Cipher is developing formulations of the pain reliever tramadol (tentative FDA approval in February 2009) and the acne treatment isotretinoin (FDA approvable letter in April 2007).
Cipher is listed on the Toronto Stock Exchange under the symbol ‘DND’ and has approximately 24 million shares outstanding. For more information, please visit www.cipherpharma.com.
For more information, please contact: Craig Armitage Investor Relations The Equicom Group (416) 815-0700 ext 278 815-0080 fax carmitage@equicomgroup.com
Larry Andrews President and CEO Cipher Pharmaceuticals (905) 602-5840 ext 324 (905) 602-0628 fax landrews@cipherpharma.com
